{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:39:04Z","timestamp":1789915144935,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ejca.2015.06.123","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T22:45:29Z","timestamp":1439246729000},"page":"2453-2464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial"],"prefix":"10.1016","volume":"51","clinical-trial-number":[{"clinical-trial-number":"2008-003658-13","registry":"10.18810\/euctr"},{"clinical-trial-number":"nct00020566","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00987636","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Henk","family":"van den Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Paulussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gw\u00e9na\u00ebl","family":"Le Teuff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Dirksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Lydia","family":"Ladenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Marec-Berard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarmila","family":"Kruseova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hjorth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"K\u00fchne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Brichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Craft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Juergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-C\u00e9cile","family":"Le Deley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2015.06.123_b0005","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","article-title":"Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone","volume":"348","author":"Grier","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2015.06.123_b0010","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1200\/JCO.1992.10.11.1737","article-title":"Ifosfamide plus etoposide in newly diagnosed Ewing\u2019s sarcoma of bone","volume":"10","author":"Meyer","year":"1992","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2015.06.123_b0015","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2165\/00128072-200103120-00003","article-title":"Ewing tumour: incidence, prognosis and treatment options","volume":"3","author":"Paulussen","year":"2001","journal-title":"Paediatr Drugs"},{"issue":"23","key":"10.1016\/j.ejca.2015.06.123_b0020","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1200\/JCO.2013.54.4833","article-title":"Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk ewing sarcoma: results of the randomized non-inferiority Euro-EWING99-R1 trial","volume":"32","author":"Le Deley","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2015.06.123_b0025","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.2003.04.106","article-title":"Single center experience of a new intensive induction therapy for ewing\u2019s family of tumors: feasibility, toxicity, and stem cell mobilization properties","volume":"21","author":"Strauss","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.123_b0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/pbc.20820","article-title":"Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial","volume":"47","author":"Juergens","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2015.06.123_b0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/biomet\/75.1.156","article-title":"The loss in efficiency from misspecifying covariates in proportional hazards regression models","volume":"88","author":"Lagakos","year":"1988","journal-title":"Biometrika"},{"key":"10.1016\/j.ejca.2015.06.123_b0040","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/biomet\/88.2.572","article-title":"On functional misspecification of covariates in the Cox regression model","volume":"88","author":"Gerds","year":"2001","journal-title":"Biometrika"},{"key":"10.1016\/j.ejca.2015.06.123_b0045","unstructured":"DCTD, NCI, NIH, DHHS. Cancer therapy evaluation program. Common toxicity criteria, Version 2 0. In; 1998."},{"issue":"4","key":"10.1016\/j.ejca.2015.06.123_b0050","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/aje\/kwf215","article-title":"Statistical analysis of correlated data using generalized estimating equations: an orientation","volume":"157","author":"Hanley","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"16","key":"10.1016\/j.ejca.2015.06.123_b0055","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression","volume":"21","author":"Heinze","year":"2002","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.ejca.2015.06.123_b0060","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival \u2013 A report from the Children\u2019s Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2015.06.123_b0065","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-11-0246","article-title":"Sex disparities in cancer mortality and survival","volume":"20","author":"Cook","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.ejca.2015.06.123_b0070","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/pbc.22940","article-title":"Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial","volume":"56","author":"Wrobel","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2015.06.123_b0075","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1200\/JCO.2012.43.8598","article-title":"Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis","volume":"31","author":"Collins","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.123_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2011.03.005","article-title":"Cytostatic drugs in infants: a review on pharmacokinetic data in infants","volume":"38","author":"van den Berg","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ejca.2015.06.123_b0085","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/bjc.1998.295","article-title":"Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo","volume":"77","author":"Brain","year":"1998","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2015.06.123_b0090","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-07-0320","article-title":"The effect of repeated administration of cyclophosphamide on cytochrome P450 2B in rats","volume":"13","author":"Afsharian","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2015.06.123_b0095","first-page":"1946","article-title":"Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines","volume":"57","author":"Chang","year":"1997","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2015.06.123_b0100","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.ejca.2015.06.123_b0105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00228-011-1132-2","article-title":"Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia","volume":"68","author":"Loryan","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ejca.2015.06.123_b0110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/00498251003713958","article-title":"Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism","volume":"40","author":"Al Koudsi","year":"2010","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.123_b0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.123_b0120","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6\u22176, is responsible for decreased expression and activity of CYP2B6 in liver","volume":"325","author":"Hofmann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.ejca.2015.06.123_b0125","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1124\/dmd.112.048108","article-title":"The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans","volume":"41","author":"Ilic","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.ejca.2015.06.123_b0130","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1124\/dmd.107.016436","article-title":"Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver","volume":"35","author":"Wortham","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.123_b0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/dmd.31.1.7","article-title":"Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels","volume":"31","author":"Chang","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.ejca.2015.06.123_b0140","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1208\/s12248-009-9135-y","article-title":"Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines","volume":"11","author":"Chang","year":"2009","journal-title":"AAPS J"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2015.06.123_b0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/03602530600569828","article-title":"Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR)","volume":"38","author":"Chang","year":"2006","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.ejca.2015.06.123_b0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/14622416.9.1.71","article-title":"Pharmacogenetics of the constitutive androstane receptor","volume":"9","author":"Lamba","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"4\u20136","key":"10.1016\/j.ejca.2015.06.123_b0155","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0960-0760(91)90280-I","article-title":"16-Ene-steroids in the human testis","volume":"40","author":"Smals","year":"1991","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"10.1016\/j.ejca.2015.06.123_b0160","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1124\/jpet.105.098319","article-title":"The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors","volume":"317","author":"Kaminski","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"6702","key":"10.1016\/j.ejca.2015.06.123_b0165","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/26996","article-title":"Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta","volume":"395","author":"Forman","year":"1998","journal-title":"Nature"},{"issue":"4\u20135","key":"10.1016\/j.ejca.2015.06.123_b0170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0960-0760(01)00057-7","article-title":"Comparative biosynthetic pathway of androstenol and androgens","volume":"77","author":"Dufort","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"10.1016\/j.ejca.2015.06.123_b0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-008-0854-z","article-title":"Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study","volume":"64","author":"Thompson","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2015.06.123_b0180","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0006-2952(92)90010-G","article-title":"Effect of age and gender on the activity of human hepatic CYP3A","volume":"44","author":"Hunt","year":"1992","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2015.06.123_b0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF03190396","article-title":"Gender difference in ifosfamide metabolism by human liver microsomes","volume":"26","author":"Schmidt","year":"2001","journal-title":"Eur J Drug Metab Pharmacokinet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915006498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915006498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T08:56:48Z","timestamp":1537433808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915006498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":37,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0959804915006498"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.06.123","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.06.123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}